Third, for locally advanced cervical cancer patients, whether PD-1/PD-L1 inhibitors can achieve better therapeutic efficacy in tumors with higher PD-L1 expression before CCRT begins will provide a better understanding of the effects of these inhibitors. The gene discussed is CD274; the disease is cervical cancer.